Amneal Pharmaceuticals welcomes new President Robert Stewart

Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. have announced that Robert Stewart, 50, will join Amneal as President, effective 25 January 2018. Stewart most recently served as Chief Operating Officer of Allergan plc. Following the successful completion of the pending combination of Amneal and Impax, he will become President and Chief Executive Officer of the combined company, to be named Amneal Pharmaceuticals, Inc., and will become a member of the board of directors. Following the close and Stewart’s appointment as President and CEO, Paul Bisaro, President and CEO of Impax, will become Executive Chairman. Amneal’s Co-CEOs and co-founders, Chirag and Chintu Patelwill serve as co-Chairmen of the combined company’s board of directors.

"We are excited that Rob will be joining Amneal. He is a great leader to inspire our team as we prepare for the expected combination with Impax and next phase of our growth in becoming a leading, affordable, healthcare company," said Chirag Patel.  Chintu Patel continued, "Rob is a highly respected leader with a wealth of pharmaceutical expertise which will further enhance our team of world-class leaders focused on creating value for patients, customers, employees and shareholders."

Stewart will work closely with Amneal’s current co-CEOs in leading Amneal’s current business and will play a key role in guiding the pre-integration planning work for the announced combination with Impax, which is currently expected to occur in the first half of 2018.

"Rob is the right executive to lead the combined company," said Paul Bisaro, President and CEO of Impax. "He brings an ideal mix of strong operating leadership, deep experience in both the brand and generics sectors, and a proven track record of driving success and capturing synergies through numerous complex integrations. I look forward to working closely with Rob again, and providing my full support to the integration effort as well as continuing to focus on creative long-term growth strategies."

Stewart commented, "I am honoured and excited to work with the Amneal and Impax teams. The combination creates a dynamic leader in generics and specialty pharmaceuticals, with a deep and rich pipeline of products and integrated global manufacturing platform for strong continued profitable growth.  I look forward to leading the teams and helping the organization achieve its long-term goals."

Stewart has 22 years of experience in global brand and generic pharmaceutical leadership, with expertise in all aspects of operations and integration. Prior to Stewart’s appointment as Chief Operating Officer of Allergan in May 2016, he served as President, Generics and Global Operations from March 2015 to May 2016; Chief Operating Officer from July 2014 to March 2015; and President, Global Operations, from August 2010 to July 2014. He joined Allergan (then Watson) in November 2009 as Senior Vice President, Global Operations. Before joining Watson, Stewart held various positions with Abbott Laboratories, Inc. from 1995 until 2009, and Hoffman La-Roche Inc. Stewart has been a board member of the National Association of Manufacturers (NAM) since September 2016, and a member of the Fairleigh Dickinson University Board of Trustees since June 2017. He earned his Bachelor’s degree in Business Management and Finance from Fairleigh Dickinson University.